Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGCG in Pulmonary Fibrosis
NCT03928847Phase 1Completed
- Start
- Dec 2017
- Primary completion
- May 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of epigallocatechin gallate in idiopathic pulmonary fibrosis (IPF) (5 arms). Primary endpoints: EGCG PK Level in Healthy Volunteers at 4 hours, Change of Serum Biomarker COMP at Day 14 and 4 more. Started Dec 2017; status: completed.
02
Drugs
epigallocatechin gallate
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03928847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928847.